ITG's Majestic Market Research Prostate Cancer Study Indicates Amgen's Xgeva Is Poised To Steal Significant Share From Novartis' Zometa; Physicians Still On The Fence About Dendreon's Provenge
To learn more about Majestic Market Research's unique healthcare research capabilities, please contact Christina Brown, Vice President of Healthcare Sales at: 646.584.6061, email@example.com, or visit our website: www.healthcare.majesticresearch.com.
2011 Investment Technology Group, Inc. All rights reserved. Not to be reproduced or retransmitted without permission. Any unauthorized usage or transmission is strictly prohibited. Investment research products and services are offered by ITG Investment Research, Inc., and not ITG Inc. (a FINRA Member firm and SIPC Member). ITG, the ITG logo, and ITG Investment Research, Inc. are trademarks of Investment Technology Group, Inc. and its subsidiaries. All other trademarks, service marks, logos, and trade names are owned by their respective owners.
Any opinions, claims, forecasts or estimates in this marketing material are subject to risks, uncertainties and assumptions and there can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates.
ITG Media/Investor Contact: J.T. Farley(212) 444-6259SOURCE ITGMMR
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV